Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.58 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29796027 | 1.00 | KDM1A (0.58) | KDM1AGPR119CHEK2HRH3USP30 | |
| SCHEMBL28059314 | 0.93 | USP30 (0.56) | KDM1AGPR119CHEK2USP30MEN1 | |
| SCHEMBL8248136 | 0.93 | USP30 (0.56) | KDM1AGPR119CHEK2USP30MEN1 | |
| SCHEMBL1032633 | 0.93 | USP30 (0.56) | KDM1AGPR119CHEK2USP30MEN1 | |
| SCHEMBL1809399 | 0.89 | GPR119 (0.57) | KDM1AGPR119CHEK2HRH3USP30 | |
| SCHEMBL30876497 | 0.89 | GPR119 (0.57) | KDM1AGPR119CHEK2HRH3USP30 | |
| SCHEMBL6481542 | 0.88 | GPR119 (0.62) | KDM1AGPR119HRH3USP30MEN1 | |
| SCHEMBL12184833 | 0.87 | USP30 (0.52) | KDM1AGPR119CHEK2USP30MEN1 | |
| SCHEMBL30388656 | 0.87 | KDM1A (0.49) | KDM1AGPR119HRH3PDE4APDE4B | |
| SCHEMBL17560083 | 0.87 | KDM1A (0.49) | KDM1AGPR119HRH3PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| WO-2024145315-A1 | TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | NORTHWESTERN UNIVERSITY (US) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024145315-A1 | TARGETED PROTEIN DEGRADERS OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | NORTHWESTERN UNIVERSITY (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4313047-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | Monte Rosa Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2022-12-22 | — | — | US | disclosed |
| WO-2022200857-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-09-29 | — | — | WO | disclosed |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-08-04 | — | — | US | disclosed |
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| EP-1753721-A1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GmbH (DE) | 2007-02-21 | — | — | EP | disclosed |
| US-20060211734-A1 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists | ELILILLY AND COMPANY (US) | 2006-09-21 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
| WO-2005121091-A1 | AROYL-O-PIPERIDINE DERIVATIVES FOR THE TREATMENT OF DIABETES-RELATED PROBLEMS | MERCK PATENT GMBH (DE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11713320-B2 | 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof | DYRK1A, WNT3, DYRK3 | KDM1A 3612/4885GPR119 2240/4885CHEK2 801/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | KDM1A 4491/4885GPR119 2263/4885CHEK2 1485/4885 |
| US-20060211734-A1 | (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl, (piperidinylsulfanyl)phenyl and (piperidinylsulfanyl)pyridinyl compounds as 5-ht1f agonists | HTR1A, HTR1F, HTR5A | KDM1A 2621/4885GPR119 329/4885CHEK2 4633/4885 |
| US-20220402921-A1 | 5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF | DYRK1A, WNT3, DYRK3 | KDM1A 3612/4885GPR119 2240/4885CHEK2 801/4885 |
| US-20220242846-A1 | ISOINDOLINONE COMPOUNDS | AOC2, AOC3, INF2 | KDM1A 4281/4885GPR119 3391/4885CHEK2 1322/4885 |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | KDM1A 446/4885GPR119 1703/4885CHEK2 68/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | KDM1A 788/4885GPR119 4245/4885CHEK2 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.